Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Mar 27, 2024
- Accession no.
- 0001415889-24-009205
- Filed
- Mar 27, 2024
- Trade date
- Mar 26, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $23.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2024 | Common Shares | SSaleDisposed | −2,114 | $10.97 | −$23,190.58 | 40,920 | Direct | |
| Mar 26, 2024 | Common Shares | MOption exerciseAcquired | +4,329 | $2.31 | +$9,999.99 | 45,249 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2024 | Options | MOption exerciseDisposed | −4,239 | $2.31 | −$9,999.99 | 182,983 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.